|
|
LETTER TO EDITOR |
|
Year : 2011 | Volume
: 28
| Issue : 2 | Page : 152-153 |
|
|
Adverse drug reaction and causality assessment scales
Syed Ahmed Zaki
Department of Pediatrics, Lokmanya Tilak Municipal General Hospital and Medical College, Sion, Mumbai - 400 022, India
Date of Web Publication | 30-Apr-2011 |
Correspondence Address: Syed Ahmed Zaki Department of Pediatrics, Lokmanya Tilak Municipal General Hospital and Medical College, Sion, Mumbai - 400 022 India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-2113.80343
How to cite this article: Zaki SA. Adverse drug reaction and causality assessment scales. Lung India 2011;28:152-3 |
Sir,
I read with interest the articles by Gupta et al and Gulati et al on adverse drug reactions of antituberculous drugs. [1],[2] I would like to make the following comments.
Adverse drug reactions (ADRs) are a major cause of morbidity, hospital admission, and even death. Hence it is essential to recognise ADRs and to establish a causal relationship between the drug and the adverse event. It is desirable that ADRs should be objectively assessed and presented based on an acceptable "Probability Scale." Many causality methods have been proposed to assess the relationship between a drug and an adverse event in a given patient, ranging from short questionnaires to comprehensive algorithms. The idea of creating a standardized assessment for the relationship-likelihood of case reports of suspected ADRs was in the hope that this would, in a structured way, lead to a reliable reproducible measurement of causality. The causality assessment system proposed by the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO-UMC), and the Naranjo Probability Scale are the generally accepted and most widely used methods for causality assessment in clinical practice as they offer a simple methodology. [3],[4] The above scales are structured, transparent, consistent, and easy to apply assessment methods. [Table 1] summarizes the "Naranjo ADR Probability Scale," which has gained popularity among clinicians because of its simplicity. [3] The WHO-UMC causality system takes into account the clinical-pharmacologic aspects, whereas previous knowledge of the ADR plays a less prominent role. [Table 2] summarizes the WHO-UMC Probability Scale. [4]
I humbly request the Editors that Lung India should use either of the above two scales while reviewing articles related to ADRs.
References | |  |
1. | Gupta KB, Kumar V, Vishvkarma S, Shandily R. Isoniazid-induced alopecia. Lung India 2011;28:60-61.  |
2. | Gulati S, Paljor HP, Mahajan R, Goel P. Erythema multiforme due to antitubercular drugs. Lung India 2011;28:76.  |
3. | Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  [PUBMED] |
4. | The use of the WHO-UMC system for standardised case causality assessment. Accessed from: http://www.who-umc.org/graphics/4409.pdf {last accessed on 2011 Feb 12].  |
[Table 1], [Table 2]
This article has been cited by | 1 |
A case of probable labetalol induced hyperkalaemia in pre-eclampsia |
|
| Binny Thomas,P. V. Abdul Rouf,Wessam El Kassem,Moza Al Hail,Derek Stewart,Asma Tharannum,Afif Ahmed,Muna Al Saadi | | International Journal of Clinical Pharmacy. 2014; 36(6): 1130 | | [Pubmed] | [DOI] | | 2 |
A Case of Vasculitis in a Breast Cancer Patient Treated with T-DM1 |
|
| Bhardwaj Aarti,Olivia Ghaw,Maria R. Robinson,Beth McLellan,Lewis R. Lipsey,Amy D. Tiersten,Gloria J. Morris | | Seminars in Oncology. 2014; | | [Pubmed] | [DOI] | | 3 |
Terlipressin-induced hyponatremic seizure in a child |
|
| Zaki, S. | | Indian Journal of Pharmacology. 2013; 45(4): 403-404 | | [Pubmed] | | 4 |
Adverse events related to cupping therapy in studies conducted in Korea: A systematic review |
|
| Tae-Hun Kim,Kun Hyung Kim,Jun-Yong Choi,Myeong Soo Lee | | European Journal of Integrative Medicine. 2013; | | [Pubmed] | [DOI] | | 5 |
Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient |
|
| Taqi, S.A. and Zaki, S.A. and Nilofer, A.R. and Sami, L.B. | | Indian Journal of Pharmacology. 2012; 44(4): 533-535 | | [Pubmed] | | 6 |
Lung India awards |
|
| Singh, V. | | Lung India. 2012; 29(1): 1 | | [Pubmed] | |
|
 |
 |
|